Management of Non-Hodgkin’s Lymphomas: Conclusions of the First Intercity Meeting, 1986

  • Bertrand Coiffier
  • André Bosly
  • Federico Caligaris-Cappio
  • Christian Gisselbrecht
  • Catherine Patte
  • Michael Schaadt
  • Michel Symann
Conference paper
Part of the ESO Intercity Report book series (ESO INTERCITY)


On 15 December 1986 in Strasbourg (France) the first Intercity Meeting of the European School of Oncology was held with a survey of the current status of non-Hodgkin’s lymphoma (NHL) management. The conclusions of this meeting are presented here. The Working Formulation for clinical use [1] (Table 1) is used throughout this paper.


Clin Oncol Complete Remission Rate Diffuse Large Cell Lymphoma Folinic Acid Rescue Bone Marrow Rescue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a Working Formulation for clinical use. The non-Hodgkin’s lymphoma pathologic classification project. Cancer 1982 (49):2112–2135Google Scholar
  2. 2.
    Nathwani BN, Metter GE, Miller TP et al: What should be the morphologic criteria for the subdivision of follicular lymphomas? Blood 1986 (68):837–845PubMedGoogle Scholar
  3. 3.
    Gospodarowicz MK, Bush RS, Brown TC, Chua T: Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1984 (10):489–497PubMedCrossRefGoogle Scholar
  4. 4.
    Rosenberg SA: The low grade non-Hodgkin’s lymphomas: challenges and opportunities. J Clin Oncol 1985 (102):596–602Google Scholar
  5. 5.
    Ezdinli EZ, Anderson JR, Melvin F, Glick JH, Davis TE, O’Connell MJ: Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 1985 (3):769–775PubMedGoogle Scholar
  6. 6.
    Cheson BD, Wittes RE, Friedman MA: Low-grade non-Hodgkin’s lymphomas revisited. Cancer Treat Rep 1986 (70):1051–1054PubMedGoogle Scholar
  7. 7.
    Anderson JR, Wilson JF, Jenkin RDT et al: Childhood non-Hodgkin’s lymphomas. The results of a randomised therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983 (308):559–565PubMedCrossRefGoogle Scholar
  8. 8.
    Patte C, Philip T, Rodary C et al: Improved survival rate in children with stage III and IV B cell non-Hodgkin’s lymphoma and leukemia using multi-agent chemotherapy. Results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 1986 (4):1219–1226PubMedGoogle Scholar
  9. 9.
    Müller-Weihrich S, Henze G, Odenwald E, Riehm H: BFM trials for childhood non-Hodgkin’s lymphomas. In: Cavalli F, Bonadonna G, Rozencweig M (eds) Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances. Martinus Nijhoff, Boston 1985 pp 633–642CrossRefGoogle Scholar
  10. 10.
    Hartmann O, Pein F, Beaujean F et al: High dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. J Clin Oncol 1984 (2):979–985PubMedGoogle Scholar
  11. 11.
    Armitage JO, Fyfe MAE, Lewis J: Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 1984 (2):889–902Google Scholar
  12. 12.
    Coltman CA, Dahlberg S, Jones SE et al: CHOP is curative in thirty per cent of patients with diffuse large cell lymphoma: a twelve Year SWOG follow-up. Proc ASCO 1986(5):774Google Scholar
  13. 13.
    Skarin AT, Canellos GP, Rosenthal D et al: Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983 (1):91–98PubMedGoogle Scholar
  14. 14.
    Fisher RI, DeVita VT, Hubbard SM et al: Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 1983 (98):304–309PubMedGoogle Scholar
  15. 15.
    Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphomas. Ann Intern Med 1985 (102):596–602PubMedGoogle Scholar
  16. 16.
    Coiffier B, Bryon PA, Berger F et al: Intensive and sequential combination chemotherapy for aggressive malignant lymphomas protocol (LNH-80). J Clin Oncol 1986 (4):147–153PubMedGoogle Scholar
  17. 17.
    Shipp MA, Harrington DP, Klatt MM et al: Identification of prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986 (4):757–765Google Scholar
  18. 18.
    Dixon DO, Neilan B, Jones SE et al: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma. The Southwest Oncology Group experience. J Clin Oncol 1986 (4):295–305PubMedGoogle Scholar
  19. 19.
    Coiffier B, Sebban C, French M et al: Aggressive lymphomas treated by intensive chemotherapy: updated results of the LNH-80 protocol with a median follow-up of 52 months. Blood 1987 (5):1394–1399Google Scholar
  20. 20.
    Wanatabe S, Sato Y, Shimoyama M, Minato K, Shimosato Y: Immunoblastic lymphadenopathy, angioimmunoblastic lymphadenopathy, and IBL-like T-cell lymphoma. A spectrum of T-cell neoplasia. Cancer 1986 (58):2224–2232CrossRefGoogle Scholar
  21. 21.
    Coiffier B, Berger F, Bryon PA, Magaud JP: Peripheral T-cell lymphomas: immunologic, histologic, clinical, and therapeutic analysis in 50 patients. Proc Am Soc Hematol 1986 (68):826Google Scholar
  22. 22.
    Kaminski MS, Coleman N, Colby TV, Cox RS, Rosenberg SA: Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 1986 (104):747–756PubMedGoogle Scholar
  23. 23.
    Cabanillas F: Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas. Hematol Oncol 1985 (3):25–31PubMedCrossRefGoogle Scholar
  24. 24.
    Cabanillas F, Hagemeiter FB, McLaughlin P et al: Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987 (5):398–406Google Scholar
  25. 25.
    Rivkin SE, Peterson BA, Jones SE: Novanrone (mitoxantrone) in the therapy of non-Hodgkin’s lymphoma: a phase II study. Protocol 3–46. Data on file, Lederle LaboratoriesGoogle Scholar
  26. 26.
    Armitage JO, Jagannath S, Spitzer G et al: High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. Eur J Cancer Clin Oncol 1986 (22):871–877PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Bertrand Coiffier
    • 1
  • André Bosly
    • 2
  • Federico Caligaris-Cappio
    • 3
  • Christian Gisselbrecht
    • 4
  • Catherine Patte
    • 5
  • Michael Schaadt
    • 6
  • Michel Symann
    • 7
  1. 1.Haematology ServiceCentre Hospitalier Lyon-Sud Pierre BéniteLyonFrance
  2. 2.Cliniques Universitaires de Mont-GodinneYvoirBelgium
  3. 3.Clinica Medica AUniversità di TorinoTurinItaly
  4. 4.Hôpital Saint-LouisParisFrance
  5. 5.Institut Gustave RoussyVillejuifFrance
  6. 6.Medizinische UniversitätsklinikKölnFederal Republic of Germany
  7. 7.Brussels BranchLudwig Institute for Cancer ResearchBelgium

Personalised recommendations